INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue82,080140,693242,275330,323
Cost of Revenue10,80320,64325,39328,854
Gross Profit71,277120,050216,882301,469
Operating Expenses
Research Development56,08562,95473,91356,781
Selling General and Administrative123,751116,443131,743143,616
Non Recurring----
Others----
Total Operating Expenses190,639200,040231,049229,251
Operating Income or Loss-108,559-59,34711,226101,072
Income from Continuing Operations
Total Other Income/Expenses Net-17,848-157,848-2,802-10,078
Earnings Before Interest and Taxes-108,559-59,34711,226101,072
Interest Expense----
Income Before Tax-126,407-217,1958,42490,994
Income Tax Expense-1,9009,64083432,941
Minority Interest----
Net Income From Continuing Ops-124,507-226,8357,59058,053
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-124,507-226,8357,59058,053
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-124,507-226,8357,59058,053